Answers are grounded in this paper and cite their sources.
Background Two-drug regimen dolutegravir/lamivudine (DTG/3TC) is recommended as an alternative to standard three-drug regimens in adult treatment guidelines. This nested pharmacokinetic sub-study within the D3/Penta 21 randomised trial (#NCT04337450) assessed DTG and 3TC concentrations and safety in virologically-suppressed children, switching to once-daily DTG/3TC fixed-dose formulations. Methods Children aged 2–<15 years received either 5/30 mg DTG/3TC dispersible tablets (DT) or 50/300 mg film-coated tablets (FCT), using WHO weight band (WB)-aligned dosing: 10–<14 kg 4 DTs; 14–<20 kg 5 DTs; 20–<25 kg 6 DTs or 1 FCT; 25–<40 kg 1 FCT. A minimum of 8-evaluable pharmacokinetic curves per WB/formulation were targeted for 24 h pharmacokinetic profiling (t = 0, 1, 2, 3, 4, 6, and 24 h post-dosing) at steady state. The number of children with DTG C trough <0.32 mg/L (EC90) and <0.064 mg/L (PA-IC90) were summarised. Safety was evaluated through 48 weeks in eligible children consented to the pharmacokinetic sub-study. Findings Between 11th May 2022 and 31st May 2023, 82 children consented for the sub-study. Seventy-two were included in the pharmacokinetic analysis; median (IQR) age was 7.1 (4.9–10.0) years and weight 21.6 (17.7–24.8) kg. DTG geometric mean (GM) (%CV) C trough and AUC 0–24 h were 0.82 (54) mg/L and 66.2 (35) h∗mg/L. 3TC GM-AUC 0–24 h was 16.2 (45) h∗mg/L. Three children had DTG C trough <0.32 mg/L, all had DTG C trough ≥0.064 mg/L. In children weighing 20–<25 kg WB and taking 1 FCT (50/300 mg) 3TC GM AUC 0–24 h was 19% higher than in children ≥25 kg (1 FCT). Of 82 children, 3 had 4 serious adverse events (SAEs) and 5 had 6 grade ≥3 adverse events (AEs). No AEs were related to DTG/3TC or resulted in treatment discontinuation. No 3TC-related AEs or laboratory abnormalities were observed in children taking FCT in the 20–<25 kg WB. PK parameters were comparable to historical paediatric data from ODYSSEY (DTG) and IMPAACT2019 (3TC) trials. Interpretation The study demonstrated adequate DTG and 3TC exposures with reassuring safety profiles using WB-based dosing, supporting licencing applications for dispersible and film-coated DTG/3TC formulations for paediatric use. Funding The D3/Penta 21 trial is sponsored by Fondazione Penta Onlus ETS (Penta) and funded by ViiV Healthcare.
No takes yet. Share an insight, caveat, or question.
Bevers et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: